Stephen Carey Sells 2,850 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.36, for a total value of $231,876.00. Following the sale, the chief financial officer directly owned 174,693 shares in the company, valued at approximately $14,213,022.48. The trade was a 1.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:ANIP traded down $1.35 during trading on Thursday, hitting $80.43. The stock had a trading volume of 192,616 shares, compared to its average volume of 375,395. ANI Pharmaceuticals, Inc. has a 12 month low of $62.60 and a 12 month high of $99.50. The company has a market capitalization of $1.83 billion, a PE ratio of 20.36 and a beta of 0.43. The firm’s fifty day moving average is $81.25 and its 200 day moving average is $79.49. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter last year, the business posted $1.70 EPS. The firm’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Pacer Advisors Inc. lifted its stake in shares of ANI Pharmaceuticals by 6.9% in the 1st quarter. Pacer Advisors Inc. now owns 85,467 shares of the specialty pharmaceutical company’s stock worth $6,572,000 after purchasing an additional 5,548 shares during the period. Bank of America Corp DE grew its position in ANI Pharmaceuticals by 229.4% during the first quarter. Bank of America Corp DE now owns 150,532 shares of the specialty pharmaceutical company’s stock valued at $11,576,000 after buying an additional 104,828 shares during the period. Janus Henderson Group PLC grew its position in ANI Pharmaceuticals by 1,308.1% during the first quarter. Janus Henderson Group PLC now owns 109,552 shares of the specialty pharmaceutical company’s stock valued at $8,425,000 after buying an additional 101,772 shares during the period. California State Teachers Retirement System grew its position in ANI Pharmaceuticals by 57.3% during the first quarter. California State Teachers Retirement System now owns 24,557 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after buying an additional 8,946 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 143 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ANIP. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Guggenheim reaffirmed a “buy” rating and issued a $124.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Finally, Canaccord Genuity Group assumed coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 16th. They set a “hold” rating and a $91.00 target price for the company. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $105.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.